Patientforskning
Logga in
Alla studier
Aktiv men inte rekryterandeFAS3INTERVENTIONELL

Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal nocturnal haemoglobinuria (PNH) is a rare blood disorder where the body's immune defence system mistakenly attacks and breaks down red blood cells. This study is an 'extension trial' testing a targeted oral medicine called iptacopan. The trial is specifically for adults who have already taken part in an earlier research study of iptacopan and are benefiting from it. The goal is to see how safe the medicine is and how well it continues to work over a longer period. Because this is an open-label study, there is no dummy pill (placebo); everyone enrolled will receive iptacopan. Doctors will keep a close eye on participants through regular health checks and blood tests to watch for side effects and ensure their blood counts stay stable.

Överblick

Status
Aktiv men inte rekryterande
Fas
FAS3
Sponsor
Novartis Läkemedel
Inskrivningsmål
208
Starta
27 Jul 2021
Beräknad slutförande
18 Oct 2027
Paroxysmal Nocturnal Hemoglobinuria

Vad handlar denna studie om?

Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, lifelong condition affecting the blood. In a healthy body, red blood cells have a natural protective shield that stops the immune system from harming them. In people with PNH, this shield is missing. As a result, part of the immune system attacks and breaks down red blood cells too quickly. This can cause severe tiredness, anaemia, dark urine, and an increased risk of dangerous blood clots.

Iptacopan is a newer medicine taken by mouth as a capsule. It works by gently blocking the specific part of the immune system that attacks the red blood cells, helping them survive normally. While earlier clinical trials showed very promising results, doctors need to know how well iptacopan works when people take it over many months or years, and whether any new side effects appear over time.

This study is known as an 'extension' or 'roll-over' trial. It provides continued access to iptacopan for patients who have already completed an earlier phase of testing and are doing well on the drug. There is no placebo in this study, meaning every single participant receives the real medicine.

Long-term studies like this are essential. They help scientists and doctors gather clear evidence about the lasting benefits and safety of new treatments, paving the way for better care and improved quality of life for people living with PNH.

Viktiga punkter

  • This study evaluates the long-term safety and benefit of iptacopan for paroxysmal nocturnal haemoglobinuria (PNH).
  • It is an extension study only open to people who have already completed an earlier iptacopan clinical trial.
  • Every participant receives the real medicine; no one is given a placebo.
  • Participants must have specific vaccinations to protect against serious bacterial infections.
  • Taking part is completely voluntary, and you can leave the study at any time.

Vem kan vara berättigad?

This study is designed for adults aged 18 and older who have a confirmed diagnosis of PNH. However, you can only take part if you have already completed a previous Phase 2 or Phase 3 clinical trial of iptacopan without reducing your dose. Your study doctor must also agree that the medicine is helping you and that your health has been stable on iptacopan alone for at least three months.

Because iptacopan works on your immune system, it can make it harder for your body to fight certain bacteria. For your safety, you must have up-to-date vaccinations against specific infections, including meningitis and pneumonia, before taking part.

You will not be able to join this study if you have had a stem cell or bone marrow transplant, or if you have a history of repeated, severe bacterial infections. You will also be excluded if you currently have an active infection, cancer, or any other serious health issue that could make taking part unsafe.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. I am aged 18 or older.
  2. I have a confirmed diagnosis of paroxysmal nocturnal haemoglobinuria (PNH).
  3. I have completed a qualifying earlier clinical trial of iptacopan.
  4. My health has been stable on iptacopan alone for at least three months.
  5. I have had the required vaccinations against meningitis and pneumonia.
  6. I have never had a stem cell transplant.
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

Taking part involves continuing to take iptacopan capsules by mouth, exactly as directed by your study doctor. You will need to attend regular clinic appointments so the medical team can monitor your health. During these visits, you will have routine blood and urine tests, physical examinations, and check-ins to discuss how you are feeling and whether you have noticed any side effects. Your study team will supply your medication and guide you through each step. The trial will last for an extended period to give you ongoing access to treatment, but you can choose to leave the study at any time.

Potentiella risker och fördelar

A key benefit of this study is that it allows you to continue receiving iptacopan without interruption, which may help keep your PNH symptoms under control and protect your red blood cells. However, all medicines carry potential risks. Because iptacopan dampens a part of your immune system, you face a higher risk of serious bacterial infections, such as meningitis. You may also experience milder side effects such as headaches or an upset stomach. You will be monitored very closely for any signs of illness. Remember that taking part is entirely voluntary, and you are free to withdraw at any point without it affecting your standard NHS care.

Locations (60)

  • City Of Hope National Med Center
    Verifierat postnummer
    Duarte, USA
  • City Of Hope
    Verifierat postnummer
    Duarte, USA
  • USC Norris Cancer Center
    Verifierat postnummer
    Los Angeles, USA
  • Univ Cali Irvine ALS Neuromuscular
    Verifierat postnummer
    Orange, USA
  • Univ of California Irvine (Chao Family Comprehensive Cancer Center)
    Verifierat postnummer
    Orange, USA
  • Lakes Research
    Verifierat postnummer
    Miami Lakes, USA
  • Augusta University Georgia
    Verifierat postnummer
    Augusta, USA
  • Augusta University
    Verifierat postnummer
    Augusta, USA
  • Montefiore medicinska centrum
    Verifierat postnummer
    The Bronx, USA
  • Cleveland Clinic Foundation
    Verifierat postnummer
    Cleveland, USA
  • Prisma Health Upstate
    Verifierat postnummer
    Greenville, USA
  • Novartis Undersökningsplats
    Verifierat postnummer
    Santo André, Brazil

Vanliga frågor

What is an extension study?

An extension study allows people who have finished an earlier trial of a medicine to keep taking it. This helps researchers see how safe and effective the treatment is over a longer time.

Will I receive a placebo (dummy pill)?

No. In this trial, every participant receives iptacopan. There is no placebo group.

Can any patient with PNH join this study?

No. This study is only open to people who have already taken part in and completed a specific earlier trial testing iptacopan.

Why do I need vaccinations before taking part?

Iptacopan calms a part of your immune system that fights off certain bugs. Vaccines against meningitis and pneumonia provide extra protection against serious infections.

What happens if I decide to stop taking part?

You can leave the study at any time for any reason. Your doctor will discuss other treatment options with you to ensure your PNH remains properly managed.

Hur du får reda på mer

Officiell rättegångsprotokoll

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.